Similarly, IL-15–based immunocytokines such as PEG-masked IL-15, ASKG915, and LH05 have demonstrated the potential for tumor-selective activation and reduced systemic toxicity in preclinical studies (76; 77). The gene discussed is IL15; the disease is neoplasm.